SunTrust Banks Comments on Charles River Laboratories International, Inc.’s FY2018 Earnings (CRL)

Charles River Laboratories International, Inc. (NYSE:CRL) – Analysts at SunTrust Banks decreased their FY2018 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a research report issued on Thursday. SunTrust Banks analyst S. Draper now forecasts that the medical research company will post earnings of $5.68 per share for the year, down from their previous estimate of $5.73. SunTrust Banks has a “Buy” rating and a $113.00 price objective on the stock.



A number of other research analysts have also recently issued reports on CRL. Robert W. Baird set a $117.00 price objective on shares of Charles River Laboratories International and gave the company a “buy” rating in a report on Monday, November 13th. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Monday, November 13th. ValuEngine cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Bank of America Corporation cut their price objective on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. Finally, BidaskClub raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $106.63.

TRADEMARK VIOLATION WARNING: “SunTrust Banks Comments on Charles River Laboratories International, Inc.’s FY2018 Earnings (CRL)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/11/20/suntrust-banks-comments-on-charles-river-laboratories-international-inc-s-fy2018-earnings-crl.html.

Shares of Charles River Laboratories International (CRL) opened at $101.39 on Monday. The firm has a market cap of $4,800.00, a P/E ratio of 19.92, a P/E/G ratio of 1.62 and a beta of 0.94. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. Charles River Laboratories International has a 12 month low of $69.51 and a 12 month high of $119.05.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.08. The business had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. Charles River Laboratories International’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.18 earnings per share.

Institutional investors and hedge funds have recently bought and sold shares of the company. Lord Abbett & CO. LLC bought a new position in Charles River Laboratories International in the 2nd quarter valued at approximately $65,915,000. FMR LLC raised its holdings in Charles River Laboratories International by 23.8% in the 2nd quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock valued at $311,458,000 after buying an additional 591,066 shares during the last quarter. Mackenzie Financial Corp raised its holdings in Charles River Laboratories International by 81.7% in the 3rd quarter. Mackenzie Financial Corp now owns 928,796 shares of the medical research company’s stock valued at $100,329,000 after buying an additional 417,739 shares during the last quarter. TimesSquare Capital Management LLC bought a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $35,182,000. Finally, FIL Ltd raised its holdings in Charles River Laboratories International by 325.4% in the 2nd quarter. FIL Ltd now owns 417,465 shares of the medical research company’s stock valued at $42,227,000 after buying an additional 319,324 shares during the last quarter. Institutional investors own 98.72% of the company’s stock.

In other news, insider Davide Molho sold 5,982 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total value of $643,364.10. Following the sale, the insider now directly owns 22,714 shares in the company, valued at approximately $2,442,890.70. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Over the last 90 days, insiders purchased 10,500 shares of company stock worth $2,885 and sold 1,012,147 shares worth $1,591,514. Corporate insiders own 2.20% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply